NASDAQ:TMDX TransMedics Group (TMDX) Stock Forecast, Price & News $56.77 -0.14 (-0.25%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$56.71▼$58.5950-Day Range$53.47▼$93.8852-Week Range$38.86▼$99.63Volume671,210 shsAverage Volume590,255 shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice Target$85.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TransMedics Group MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside49.7% Upside$85.00 Price TargetShort InterestBearish14.63% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 5 Articles This WeekInsider TradingSelling Shares$2.75 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector555th out of 969 stocksElectromedical Equipment Industry14th out of 20 stocks 3.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $85.00, TransMedics Group has a forecasted upside of 49.7% from its current price of $56.77.Amount of Analyst CoverageTransMedics Group has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.63% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in TransMedics Group has recently increased by 14.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 3.3 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for TransMedics Group this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows3 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold 1,676.46% more of their company's stock than they have bought. Specifically, they have bought $155,000.00 in company stock and sold $2,753,520.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($0.51) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -99.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -99.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 9.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TransMedics Group (NASDAQ:TMDX) StockTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesSeptember 28, 2023 | finance.yahoo.com3 Best Stocks to Buy With $300 Right NowSeptember 28, 2023 | finance.yahoo.comChecking In on the Fed, FedEx, and TransMedicsSeptember 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 22, 2023 | finance.yahoo.comTransMedics Group, Inc.'s (NASDAQ:TMDX) Shift From Loss To ProfitSeptember 21, 2023 | finance.yahoo.comBuy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged GainsAugust 28, 2023 | finance.yahoo.comTransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 19, 2023 | fool.comTransMedics Group (NASDAQ: TMDX)August 17, 2023 | finance.yahoo.comTransMedics (TMDX) Acquires Summit Aviation for Organ TransplantSeptember 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 16, 2023 | finance.yahoo.comTransMedics Completes Acquisition of Summit AviationAugust 12, 2023 | finance.yahoo.comAnalysts' Revenue Estimates For TransMedics Group, Inc. (NASDAQ:TMDX) Are Surging HigherAugust 8, 2023 | msn.comTransMedics: Aircraft Additions Bring Immense Gross-Value Add, Reiterate BuyAugust 6, 2023 | finance.yahoo.com2 Unstoppable Growth Stocks You Can Buy With $200 Right NowAugust 5, 2023 | msn.comTD Cowen Maintains Transmedics Group (TMDX) Outperform RecommendationAugust 5, 2023 | finance.yahoo.comIs TransMedics Group, Inc. (NASDAQ:TMDX) Trading At A 26% Discount?August 4, 2023 | finance.yahoo.comWhy Shares of TransMedics Group Are Falling FridayAugust 3, 2023 | msn.comDow Jones Futures Rise: Apple, Amazon Lead Earnings Movers Late; Jobs Report On TapAugust 3, 2023 | finance.yahoo.comTransMedics Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | msn.comTransMedics to acquire U.S. charter flight operator Summit AviationAugust 3, 2023 | finance.yahoo.comTransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to LifeAugust 3, 2023 | finance.yahoo.comBridge to Life Divests Certain Assets to TransMedicsAugust 1, 2023 | finance.yahoo.comTransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ TransplantationJuly 28, 2023 | seekingalpha.comHeadwaters Capital - TransMedics: 'Heart In A Box' Technology Revolutionizing The Organ Transplant IndustryJuly 27, 2023 | finance.yahoo.comTransMedics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 27, 2023 | finance.yahoo.comTransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate SecretaryJuly 20, 2023 | finance.yahoo.comTransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023July 19, 2023 | markets.businessinsider.comTransMedics Revolutionizing Global Organ Transplant Market: Analyst Initiates With Buy RatingSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees212Year FoundedN/APrice Target and Rating Average Stock Price Forecast$85.00 High Stock Price Forecast$110.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+49.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,230,000.00 Net Margins-11.77% Pretax Margin-11.72% Return on Equity-9.98% Return on Assets-4.65% Debt Debt-to-Equity Ratio3.48 Current Ratio20.70 Quick Ratio19.74 Sales & Book Value Annual Sales$93.46 million Price / Sales19.80 Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book9.67Miscellaneous Outstanding Shares32,600,000Free Float30,416,000Market Cap$1.85 billion OptionableNot Optionable Beta1.52 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 55)Founder, Pres, CEO & Director Comp: $1.46MMr. Stephen Gordon (Age 55)CFO, Treasurer & Sec. Comp: $744.62kDr. Tamer I. Khayal M.D. (Age 54)Chief Commercial Officer Comp: $748.78kMs. Miriam C. Provost Ph.D. (Age 62)VP of Global Regulatory Affairs Comp: $535.93kMr. Nick Corcoran (Age 41)Sr. VP of Supply Chain & Operations Mr. Mark AndersonSr. Director of Technology Devel.Mr. Anil RanganathSr. VP, Gen. Counsel & Corp. Sec.Ms. Susan GoodmanVP of HRMore ExecutivesKey CompetitorsIntegerNYSE:ITGRInModeNASDAQ:INMDLivaNovaNASDAQ:LIVNBioLife SolutionsNASDAQ:BLFSOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsWaleed H HassaneinSold 7,500 sharesTotal: $511,950.00 ($68.26/share)Miriam ProvostSold 2,708 sharesTotal: $180,136.16 ($66.52/share)David WeillBought 2,500 shares on 8/29/2023Total: $155,000.00 ($62.00/share)Alberta Investment Management CorpBought 4,834 shares on 8/24/2023Ownership: 0.015%Osaic Holdings Inc.Bought 14,023 shares on 8/21/2023Ownership: 0.187%View All Insider TransactionsView All Institutional Transactions TMDX Stock - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price forecast for 2023? 8 Wall Street research analysts have issued 1-year price objectives for TransMedics Group's stock. Their TMDX share price forecasts range from $74.00 to $110.00. On average, they expect the company's stock price to reach $85.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2023? TransMedics Group's stock was trading at $61.72 at the beginning of the year. Since then, TMDX shares have decreased by 8.0% and is now trading at $56.77. View the best growth stocks for 2023 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.12. The company had revenue of $42.46 million for the quarter, compared to the consensus estimate of $42.42 million. TransMedics Group had a negative net margin of 11.77% and a negative trailing twelve-month return on equity of 9.98%. The firm's revenue was up 136.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.41) EPS. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), Innovator IBD 50 ETF (FFTY), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), BNY Mellon Innovators ETF (BKIV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $180.00 million-$190.00 million, compared to the consensus revenue estimate of $173.91 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. What is TransMedics Group's stock symbol? TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX." How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TransMedics Group's stock price today? One share of TMDX stock can currently be purchased for approximately $56.77. How much money does TransMedics Group make? TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.85 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. How many employees does TransMedics Group have? The company employs 212 workers across the globe. How can I contact TransMedics Group? TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com. This page (NASDAQ:TMDX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.